UK markets closed

Pfizer Inc. (PFE)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
25.26-1.01 (-3.84%)
At close: 04:01PM EDT
25.31 +0.05 (+0.20%)
After hours: 04:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close26.27
Open26.27
Bid25.31 x 1400
Ask25.32 x 2200
Day's range25.25 - 26.43
52-week range25.23 - 40.37
Volume47,041,491
Avg. volume42,211,908
Market cap143.036B
Beta (5Y monthly)0.57
PE ratio (TTM)68.27
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.68 (6.40%)
Ex-dividend date25 Jan 2024
1y target estN/A
  • The Telegraph

    Wall Street plunges after US inflation shock

    US stock markets plunged amid fears of stagflation in the American economy, which grew at its slowest pace in nearly two years just as inflation jumped.

  • Reuters

    UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

  • Reuters

    GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

    (Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.